- Home
- CMMB vs TLPH Comparison
CMMB vs TLPH Comparison
Compare CMMB & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- TLPH
- Stock Information
- Founded
- CMMB 2004
- TLPH 2005
- Country
- CMMB Israel
- TLPH United States
- Employees
- CMMB N/A
- TLPH N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- TLPH Health Care
- Exchange
- CMMB Nasdaq
- TLPH Nasdaq
- Market Cap
- CMMB 23.0M
- TLPH 10.6M
- IPO Year
- CMMB N/A
- TLPH 2011
- Fundamental
- Price
- CMMB $1.16
- TLPH $0.52
- Analyst Decision
- CMMB Strong Buy
- TLPH Strong Buy
- Analyst Count
- CMMB 2
- TLPH 1
- Target Price
- CMMB $8.50
- TLPH $6.00
- AVG Volume (30 Days)
- CMMB 182.0K
- TLPH 49.7K
- Earning Date
- CMMB 08-20-2025
- TLPH 08-13-2025
- Dividend Yield
- CMMB N/A
- TLPH N/A
- EPS Growth
- CMMB N/A
- TLPH N/A
- EPS
- CMMB N/A
- TLPH N/A
- Revenue
- CMMB N/A
- TLPH $27,000.00
- Revenue This Year
- CMMB N/A
- TLPH N/A
- Revenue Next Year
- CMMB N/A
- TLPH $14,533.26
- P/E Ratio
- CMMB N/A
- TLPH N/A
- Revenue Growth
- CMMB N/A
- TLPH N/A
- 52 Week Low
- CMMB $0.87
- TLPH $0.43
- 52 Week High
- CMMB $2.55
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- CMMB 38.60
- TLPH 61.24
- Support Level
- CMMB $1.17
- TLPH $0.44
- Resistance Level
- CMMB $1.20
- TLPH $0.52
- Average True Range (ATR)
- CMMB 0.05
- TLPH 0.03
- MACD
- CMMB 0.00
- TLPH 0.01
- Stochastic Oscillator
- CMMB 16.46
- TLPH 93.89
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.